Prof Jeremy Whelan

Dr Jeremy WhelanTel: 020 3447 9346
Fax: 020 3447 9055
Email: Med.OncSarcomaPA@uclh.nhs.uk

Location:
University College Hospital

Specialities:
Long-term-follow-up (LTFU): Late effects of Cancer, Sarcoma - The London Sarcoma Service, Children and young people's cancer services

Professional background

Prof Whelan was appointed as a Consultant Oncologist at UCLH in 1996 and since then has developed services for sarcomas and for young people with cancer. In conjunction with the Royal National Orthopaedic Hospital, UCLH now hosts one of the largest sarcoma services in Europe with particular expertise in the management of bone sarcomas.

Current Positions:

Consultant Medical Oncologist
Department of Oncology
UCL Hospitals NHS Foundation Trust
250 Euston Road
London NW1 2PG
and
Southend General Hospital
Prittlewell Chase
Westcliffe on Sea
Essex SS0 0RY

Honorary Senior Lecturer
Department of Oncology
University College London Medical School
91 Riding House Street
London W1N 8AA

Co-chair of the Sarcoma Advisory Group of the London and South East Sarcoma Network serving a population of approximately 15 million people (www.lsesn.nhs.uk ).

Chair of the National Clinical Reference Group for Sarcoma

Research interests

UCLH is the largest single institution contributing patients to current international clinical trials in osteosarcoma and Ewing’s tumours.

Prof Whelan leads an extensive programme of clinical research in sarcomas. He is a  chief investigator of the international randomised study for osteosarcoma, EURAMOS 1, which has completed accrual of over 2000 patients in Europe and the United States.

He has also taken an active role in national cancer policy developments in his areas of expertise. He is currently a member of the National Cancer Research Institute Teenage and Young Adult Clinical Studies Group and NCRI Sarcoma Clinical Studies Group.

Prof Whelan is involved in BRIGHTLIGHT - a large scale group of research projects which look at the quality of the provision of services for people aged 13-24 with cancer.

Publications

Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan JS, Strauss SJ. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? BMC Cancer. 2014;14(1):23.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J-Y, Kerst JM, Sufliarsky J, Whelan JS, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PCW, dei Tos AP, van der Graaf W, for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncology 2014 http://dx.doi.org/10.1016/S1470-2045(14)70063-4
Fern L, Lewandowski J, Coxon K, Whelan JS. Available, Accessible, Aware, Appropriate, and Acceptable—a strategy for improving participation of teenagers and young adults in cancer clinical trials. Lancet Oncology 2014;15:e341-50

Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Bérard P, Van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U. Cyclophosphamide compared to ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomised noninferiority Euro-E.W.I.N.G.99 R1 trial. J Clin Oncol 2014:32;2440-8

Rothermundt C, Whelan JS, Dileo P, Strauss S, Coleman J, Briggs T, Haile S, Seddon B. What is the role of routine follow up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer 2014 1–7 | doi: 10.1038/bjc.2014.200

Frezza, AM, Whelan JS, Dileo P. Trabectedin for desmoplastic small round cell tumours: a possible treatment option? Clinical Sarcoma Research 2014;4:3

Anninga JK, Cleton-Jansen AM, Hassan, AB, Amary F, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jürgens H, Kempf-Bielack B, Kovar H, Myklebost O, Nathrath M, Picci P, Riegman P, Schilham M, Soliman R, Stark D, Strauss S, Sydes M, Tarpey P, Thomas D, Whelan JS, Wilhelm Zamzam M, Gelderblom H, Bielack S.  Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology. Clinical Sarcoma Research 2014, 4:4

Michelagnoli MP and Whelan JS. A Phase II Study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing Sarcoma. Ped Blood Cancer 2015:62;158-9
Whelan JS, Bielack S,  Marina N,  Smeland S,  Jovic G,  Hook JM,  Krailo M,  Anninga J,  Butterfass-Bahloul T,  Böhling T,  Calaminus G,  Capra M,  Deffenbaugh C,  Dhooge C,  Eriksson M,  Flanagan AM,  Gelderblom A,  Goorin A,  Gorlick R,  Gosheger G,  Grimer RJ,  Hall KS,  Helmke K,  Hogendoorn PC,  Jundt G,  Kager L,  Kuehne T,  Lau C,  Letson GD,  Meyer J,  Meyers P,  Morris C,  Mottl H,  Nadel H,  Nagarajan R,  Randall RL,  Schomberg P,  Schwarz R,  Teot LA,  Sydes MR,  Bernstein M  on behalf of the EURAMOS collaborators.     EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2015:26:407-14

Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci D, Casanova J, Esler C, Ferrari S, Funovics P, Gerrand C, Grimer R, Gronchi A, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan JS.  Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer 2015;51:374-81

Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth, A, Fortpied, C, Eng, C, Peckitt, C, Coens, C, Pettaway, C, Arnold, D, Hall, E , Marshall, E, Sclafani, F, Hatcher H Earl, H Ray-Coquard, I, Paul, J, Blay, J. Y, Whelan, J, Panageas, K, Wheatley, K, Harrington, K, Licitra, L, Billingham, L, Hensley, M, McCabe, M, Patel, P. M, Carvajal, R, Wilson, R., Glynne-Jones, R, McWilliams, R, Leyvraz, S, Rao, S, Nicholson, S, Filiaci, V, Negrouk, A, Lacombe, D., Dupont, E, Pauporte, I, Welch, J. J, Law, K, Trimble, T, Seymour, M. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015;51(3):271-81. Epub 2014/12/30.
Gaspar N, Hawkins D, Dirksen U, Lewis I, Ferrari S, Le Deley M-C, Kovar H, Grimer R, Whelan JS, Claude L, Delattre O, Paulussen M, Picci P, Sundby-Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein M, Marec Berard P, Brennan B, Craft AW, Womer R, Juergens H, Oberlin O. Ewing sarcoma: current management and future approaches through collaborations. J Clin Oncol (in press)

Bielack S, Smeland S, Whelan J, Marina N, et al. MAP plus maintenance pegylated interferon-alpha-2b (MAPifn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histological response to preoperative MAP: First results of the EURAMOS-1 Good Response randomized controlled trial. J Clin Oncol 2015;33: 2279-87 Doi 10.1200/JCO.2014.60.0734
Taylor R, Mohain J, Gibson F, Solanki A, Whelan J, Fern L. Novel participatory methods of involving patients in research: naming and branding a longitudinal cohort study, BRIGHTLIGHT. BMC Methodol 2015;15:20 Doi 10.1186/s12874-015-0014-1

Di Giannatale A, et al Primary cutaneous and subcutaneous Ewing sarcoma: description of 56 new cases and comparison with the literature. Ped Blood Cancer Doi 10.1002/pbc.25535
O’Hara C, Moran A, Whelan JS, Hough R, Stiller C, Stevens M, Stark D, Feltbower D, McCabe M. Trends in survival for teenagers and young adults with cancer in the UK 1992-2006 Eur J Cancer (in press)

Seddon BM, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A’Hearn R, Whelan J, Judson I. A phase II trial to assess the activity of gemcitabine and docetaxel in as fist line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Research 2015;5:13

Fidler  M, Frobisher C, Guha J, Wong K, Kelly J, Winter D, L, Sugden E, Duncan R, Whelan J, Reulen R, Hawkins M.  Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study.  Br J Cancer 2015;112:1857-65 Doi 10.1038/bjc.2015.159

Sharma A,  Brown K, Skinner J, Whelan JS, Fox M.  Extraskeletal Ewing’s Sarcoma Arising from the Sciatic Nerve: A Diagnostic Challenge. Case Reports in Surgery 2015;2015:3 Article ID 172635  doi.org/10.1155/2015/172635

Bolling T, Braun-Munzinger G, Burdach S, Calaminus G, Craft A, Delattre O, Deley M C, Dirksen U, Dockhorn-Dworniczak B, Dunst J, Engel S, Faldum A, Frohlich B, Gadner H, Gobel U, Gosheger G, Hardes J, Hawkins D S, Hjorth L, Hoffmann C, Kovar H, Kruseova J, Ladenstein R, Leuschner I, Lewis I J, Oberlin O, Paulussen M, Potratz J, Ranft A, Rossig C, Rube C, Sauer R, Schober O, Schuck A, Timmermann B, Tirode F, van den Berg H, van Valen F, Vieth V, Willich N, Winkelmann W, Whelan J, Womer RB. Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe. Klin Padiatr 2015; 227(03): 108-115 DOI: 10.1055/s-0035-1545263

van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan JS, Ladenstein R, Marec-Berard P, Kruseova J, Horth L, Kuhne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley M-C. Impact of gender on efficacy and acute toxicity of alkylating agent –based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. Eur J Cancer 2015 (in press)

Taylor R, Fern L, Solanki A, Carluccio A, Pye J, jeans D, Frere-Smith T, Gibson F, Barber J, Raine R, Stark D, Feltbower R, Pearce S, Whelan JS. Development and validation of the BRIGHTLIGHT Survey, a patient-reported experience measure for young people with cancer. Health and Quality of Life Outcomes (2015) 13:107 DOI 10.1186/s12955-015-0312-7

Grimer R, Athanasou N, Gerrand C, Judson I, Lewis I, Morland B, Peake D, Seddon B, Whelan J.  UK Guidelines for the management of bone sarcomas. Sarcoma. 2010;2010:317462. Epub 2010 Dec 29.

Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 Suppl 5 204-13

Whelan JS, McTiernan A, Cooper N, Wong Y, Francis M, Vernon S, Strauss S..Incidence and survival of malignant bone sarcomas in England 1979-2007  Int Journal of Cancer, DOI: 10.1002/ijc.26426

Strauss SJ, Ng T, Mendoza-Naranjo A, Whelan J, Sorensen P Understanding micrometastatic disease and “anoikis” resistance in Ewing’s family Tumours (EFT) and osteosarcoma.. The Oncologist 2010;15:627-35

Ladenstein R, Potschger U, Le Deley M-C, Whelan JS, Paulussen M, Oberlin O,  van den Berg H, Dirksen L, Hjorth L, Michon J, Lewis I, Craft A, Jurgens H Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial.. J Clin Oncol 2010 10;28:3284-91

Juergens H, Daw N, Geoerger B, Ferrari S, Villarroel M,  Aerts I, Whelan J, Dirksen U, Hixon M, Yin D, Wang T, Green S, Paccagnella L, Gualberto A.Preliminary Efficacy of the Anti-Insulin Like Growth Factor type 1 Receptor Antibody Figitumumab in Patients with Refractory Ewing Sarcoma. J Clin Onc 2011 DOI:10.1200/JCO.2010.33.0670

Whelan JS, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M The role of interferons in the treatment of osteosarcoma.. Pediatric Blood Cancer 2010;54:350-54

Gelderblom AH, Jinks R, Sydes M, Bramwell VH, van Glabbeke M, Grimer RJ, Hogendoorn PCW, McTiernan A, Lewis I, Nooij M, Taminiau AHM, Whelan JS Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup randomised controlled trials.. Eur J Cancer 2011;47:895-902

Johannson AM, Mayne N, Perisoglou M, Whelan JS, Karlsson MO Standing JF Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis in Osteosarcoma. Therapeutic Drug Monitoring., in press

Windsor RE, Kallis C, Strauss SJ, Wood N, Whelan JS Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study..  Cancer, 2011 DOI: 10.1002/cncr.26472

Whelan JS, Jinks R.C, McTiernan A, Sydes MR, Hook JM, Trani L, Uscinska B, Bramwell  B Lewis IJ, Nooij  M, van Glabbeke M, Grimer RJ, Hogendoorn PCW, Taminiau AHM, Gelderblom H. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol 2011; doi: 10.1093/annonc/mdr491

McTiernan A, Jinks RC, Sydes MR, Uscinska B, Hook JM, van Glabbeke M, Bramwell  V Lewis IJ, Taminiau AHM, Nooij  M, Hogendoorn PCW, Gelderblom H, Whelan JS on behalf of the European Osteosarcoma Intergroup.Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup   Eur J Cancer 2011 doi: 10.1016/j.ejca.2011.09.012

Fern LA, Campbell C, Eden TO, Grant R. Lewis IJ, Macleod U, Weller D, Whelan JS. How frequently do young people with potential cancer symptoms present in primary care? British Journal of General Practice 2011;61(586):e223-30. Erratum in: Br J Gen Pract. 2011 Jun;61(587):382

Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J,  Bielack S, Kager L, Kuehne T, Sydes M, Gelderblom H, Ferrari S, Picci P, Smeland S, Eriksson M, Petrilli AS, Bleyer A, Thomas D.  Benefits and adverse events in younger versus older patients receiving (neo)-adjuvant chemotherapy for osteosarcoma: findings from a 4,403 patient meta-analysis. J Clin Oncol (in press)

Whelan J, Khan A, Sharma A, Rothermundt C, Dileo P, et al. Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas. Clin Sarcoma Res. 2012 Sep 21;2(1):12.

Morland B, Platt, K, Whelan JS. A phase II study of irinotecan (CPT-11) in high risk Ewing’s sarcoma. A EURO-E.W.I.N.G study. Ped Blood Cancer 2013 Sep 9. doi: 10.1002/pbc.24767

Bielack S, Kempf-Bielack B, Von Kalle T, Schwarz R, Wirth T, Kager L, Whelan J.Controversies in childhood osteosarcoma. Minerva Pediatr. 2013;65(2):125-48. Epub 2013/04/25.

Vincenzi B, Frezza AM, Schiavon G, Santini D, Dileo P, Silletta M, Delisi D, Bertoldo F, Badalamenti G, Baldi GG, Zovato S, Berardi R, Tucci M, Silvestris F, Dei Tos AP, Tirabosco R, Whelan JS, Tonini G. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res. 2013 Apr 17;3(1):6.

Fern L and Whelan J. National Cancer Research Institute Teenage and Young Adult Clinical Studies Group: The United Kingdom Approach to Research. International Perspectives on AYAO, Part 4 Journal of Adolescent and Young Adult Oncology. December 2013, 2(4): 161-166. doi:10.1089/jayao.2012.0030.

Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?.Is [BMC Cancer. 2014 Jan 15;14:23.

Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer. 2014 May 13;110(10):2420-6. doi: 10.1038/bjc.2014.200. Epub 2014 Apr 15

Anna Maria Frezza, Jeremy S Whelan, and Palma Trabectedin for desmoplastic small round cell tumours: a possible treatment option? Dileo Clin Sarcoma Res. 2014 Apr 25;4:3.

Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J-Y, Kerst JM, Sufliarsky J, Whelan JS, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PCW, dei Tos AP, van der Graaf W for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncology 2014 http://dx.doi.org/10.1016/S1470-2045(14)70063-4

GMC/GDC number: 2915300